Peptide Recovery Stack (BPC-157 + TB-500)

B84· Mostly solid

Public • 08 Apr 2026

BPC-157 & TB-500 are the two most researched recovery peptides, with complementary mechanisms. BPC-157 (Body Protection Compound) accelerates tendon, ligament, & gut repair via angiogenesis & growth factor upregulation. TB-500 (Thymosin Beta-4) promotes systemic tissue repair, reduces inflammation, & improves mobility. GHK-Cu supports collagen synthesis & skin regeneration. Note: all three are research compounds not approved for human therapeutic use.

← Back Try alternative layout

Buy stack

Peptide Recovery Stack (BPC-157 + TB-500)

recovery peptides tissue-repair

BPC-157

2× weekly subcutaneous

LOW

0mg

TB500 (TB4 / Thymosin Beta-4)

2× weekly subcutaneous

LOW

5mg

GHK-Cu

Daily topical or subcutaneous

MODERATE

1mg

No interactions detected

Each dose includes evidence rationale · doses personalized to your weight

Stack note

Private note on this stack

Track how this stack felt, what you want to change next cycle, or anything you want to save privately in your member zone.

AI risk assessment

Context: No wearable data

PROAI risk assessment is available with Pro.

See plans

Stack pre-check

No personal data connected — connect wearables or upload bloodwork for a personalised check

Clean

Supplements

Training load

Unknown

No flags

No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis

Pharmacokinetic + pair-level checks

Timing optimizations

BPC-157

Take ~1h before the intended effect window

Reaches peak plasma concentration in ~1h. Half-life ~4h.

TB500 (TB4 / Thymosin Beta-4)

Take ~1h before the intended effect window

Reaches peak plasma concentration in ~1h. Half-life ~4h.

GHK-Cu

Take ~15 min before the intended effect window

Reaches peak plasma concentration in ~15 min. Half-life ~0.5h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Supplements

3 items

BPC-157Low

2× weekly subcutaneous • Injectable •

Promotes tendon-to-bone healing, gut mucosal repair, & angiogenesis via VEGFR2 & growth hormone receptor upregulation.

Buy ingredient →

0mg

Safety / pharmacokinetics

Low

Population: Healthy volunteers

Study type: Registered phase 1 trial (results not posted)

Dose context: — • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted & the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial•https://clinicaltrials.gov/study/NCT02637284

Musculoskeletal healing (preclinical)

Low

Population: Animal injury models (multiple tissues)

Study type: Narrative review of preclinical evidence

Dose context: —

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone & GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)•https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

Soft tissue healing signals (preclinical)

Low

Population: Animal models (multiple tissues)

Study type: Review (preclinical-focused)

Dose context: —

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)•https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/

TB500 (TB4 / Thymosin Beta-4)Low

2× weekly subcutaneous • Injectable •

Systemic tissue repair & anti-inflammatory via actin-binding, promoting cell migration & reducing fibrosis.

Buy ingredient →

5mg

Wound healing

Low

Population: Rat full-thickness wound model

Study type: Preclinical animal study

Dose context: —

TB4 accelerated wound healing endpoints in a rat model compared with controls.

Citation: Malinda et al., J Invest Dermatol (1999)•DOI: 10.1046/j.1523-1747.1999.00708.x•https://pubmed.ncbi.nlm.nih.gov/10469335/

Wound healing (clinical development)

Low

Population: Patients with venous stasis ulcers

Study type: Registered phase 2 trial (TB4 gel)

Dose context: — • Duration: Up to 84 days (per registry)

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial & endpoint reporting.

Citation: ClinicalTrials.gov NCT00832091 — Thymosin Beta 4 in Venous Stasis Ulcers•https://clinicaltrials.gov/study/NCT00832091

Wound healing (reviewed clinical context)

Low

Population: Stasis and pressure ulcer clinical programs

Study type: Review article

Dose context: —

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Citation: Treadwell et al., Ann N Y Acad Sci (2012) — The regenerative peptide thymosin β4 accelerates the rate of dermal healing•https://pubmed.ncbi.nlm.nih.gov/23050815/

GHK-CuLow

Daily topical or subcutaneous • Topical or injectable •

Copper peptide that stimulates collagen & elastin synthesis, supporting skin regeneration & wound healing.

Buy ingredient →

1mg

Extracellular matrix remodeling via MMP-2 upregulation

Low

Population: In vitro (human fibroblast cultures)

Study type: In vitro mechanistic study

Dose context: — • Duration: Cell culture (acute exposure)

GHK-Cu significantly increased MMP-2 (matrix metalloproteinase-2) protein levels and corresponding mRNA in fibroblast culture media. TIMP-1 and TIMP-2 secretion also rose, indicating balanced matrix remodeling activity. The copper component was essential - GHK peptide alone produced no effect. Authors conclude GHK-Cu acts as both an activator of connective tissue production and a regulator of extracellular matrix remodeling.

Citation: Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65.•DOI: 10.1016/s0024-3205(00)00803-1•https://pubmed.ncbi.nlm.nih.gov/11045606/

Grade is LOW because this is an in vitro study only - no human or animal data. Results are mechanistically plausible and consistent with GHK-Cu's known biology, but cannot be directly extrapolated to dosing or clinical outcomes.

Skin appearance / remodeling (summary of clinical + mechanistic evidence)

Moderate

Population: Humans (cosmetic/dermatologic contexts) + preclinical

Study type: Review

Dose context: —

Review summarizes reported improvements in some skin measures & broad tissue-remodeling biology; quality & comparators vary widely. The authors note a surprising absence of rigorous modern clinical trials for GHK-Cu in anti-wrinkle applications despite widespread cosmetic use.

Citation: Pickart et al., Molecules (2018) — Regenerative and Protective Actions of the GHK-Cu Peptide•DOI: 10.3390/ijms19071987•https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/

Wrinkle improvement (objective measures)

Low

Population: Adults using topical copper tripeptide complex

Study type: Clinical study (objective evaluation)

Dose context: —

One objective evaluation reported no significant improvement in wrinkles/overall skin quality, though patient satisfaction differed; underscores mixed results across formulations & endpoints.

Citation: Miller et al., Arch Facial Plast Surg (2006) — Topical copper tripeptide complex evaluation•DOI: 10.1001/archfaci.8.4.252•https://www.liebertpub.com/abs/doi/10.1001/archfaci.8.4.252